Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 171. Click on ID to see further detail.
| IDOV_59 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_60 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result90% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_61 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result40% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_62 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result2% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_63 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.001 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_64 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result90% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_65 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result60% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_66 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result4% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_67 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result1% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_68 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.001 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_69 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_70 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result96% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_71 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result80% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_72 | Virus nameAdenovirus | Virus strainAd5WS1 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the E1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result20% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_73 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_74 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_75 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_76 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_77 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_78 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_79 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_80 | Virus nameAdenovirus | Virus strainAdLacZ | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1/E3-deleted mutant | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_81 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_82 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result85% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_83 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result35% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_84 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (YB-1 gene knockdown) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result1% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_85 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.001 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_86 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result90% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_87 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result20% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_88 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result2% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_89 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged YB-1 gene overexpressed) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result1% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_90 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.001 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_91 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.01 MOI | In-vitro result100% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_92 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration0.1 MOI | In-vitro result94% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_93 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration1 MOI | In-vitro result75% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_94 | Virus nameAdenovirus | Virus strainAd5GS3 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationE1B55K-deleted mutant driven by the MDR1 promoter | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNA | Origin of cell lineHuman breast cancer line | Cell lineMCF-7 (HA-tagged mutant YB-1(S102A) gene overexpression, mutation at Akt phosphorylation site which leads to failed nuclear translocation) | Concentration of cell lineNA | In-vitro toxicityNA | AssayCrystal violet staining | In-vitro virus concentration10 MOI | In-vitro result16% cancer cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26515462 |
| IDOV_2222 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell survival after day 1 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2223 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell survival after day 2 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2224 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.01 MOI | In-vitro result70% cell survival after day 3 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2225 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.01 MOI | In-vitro result40% cell survival after day 4 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2226 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.01 MOI | In-vitro result20% cell death after day 5 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2227 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.1 MOI | In-vitro result90% cell survival after day 1 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2228 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.1 MOI | In-vitro result60% cell survival after day 2 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2229 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.1 MOI | In-vitro result30% cell survival after day 3 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2230 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.1 MOI | In-vitro result10% cell survival after day 4 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2231 | Virus nameHerpes simplex virus | Virus strainHSV-1-G47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineState key laboratory of oncology China | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+5 cells per well | In-vitro toxicityNA | AssayX-gal staining and MTT assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell death after day 5 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCaspase activation | Immunogenic effectNA | Clinical trialNA | PMID22108767 |
| IDOV_2634 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result90% cell survival after 3 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2635 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result60% cell survival after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2640 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result60% cell survival after 3 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2641 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result30% cell survival after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2642 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result60% cell survival after 3 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2643 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result20% cell survival after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2654 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.001 MOI | In-vitro result80% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2655 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.01 MOI | In-vitro result80% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2656 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result60% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2657 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result50% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2658 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug Bvdu (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 MOI | In-vitro result30% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2659 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.001 MOI | In-vitro result70% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2660 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.01 MOI | In-vitro result70% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2661 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result30% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2662 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result20% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2663 | Virus nameAdenovirus | Virus strainSG500-dNK | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAddition of deoxyribonucleoside kinase | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 MOI | In-vitro result10% cell survival | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedCombination of drug and virus increase the apoptosis process | Immunogenic effectNA | Clinical trialNA | PMID23000515 |
| IDOV_2806 | Virus nameAdenovirus | Virus strainG47-delta | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus strain in combination with palcitaxel (1.5 nm) | Immune gene insertion in viral genomeNo | Source of cell lineSun-sen university cancer centre, china | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line2000 cells per well | In-vitro toxicityNA | AssayCell counting kit-8 | In-vitro virus concentration0.25 MOI | In-vitro result50% cells viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedMitotic arrest and induction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID23525624 |
| IDOV_2807 | Virus nameAdenovirus | Virus strainG47-delta | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus strain in combination with palcitaxel (3 nm) | Immune gene insertion in viral genomeNo | Source of cell lineSun-sen university cancer centre, china | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line2000 cells per well | In-vitro toxicityNA | AssayCell counting kit-8 | In-vitro virus concentration0.5 MOI | In-vitro result40% cells are viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedMitotic arrest and induction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID23525624 |
| IDOV_2808 | Virus nameAdenovirus | Virus strainG47-delta | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus strain in combination with palcitaxel (4.5 nm) | Immune gene insertion in viral genomeNo | Source of cell lineSun-sen university cancer centre, china | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line2000 cells per well | In-vitro toxicityNA | AssayCell counting kit-8 | In-vitro virus concentration0.75 MOI | In-vitro result30% cells are viable | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedMitotic arrest and induction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID23525624 |
| IDOV_3006 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3007 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result90% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3008 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result80% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3009 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration3 MOI | In-vitro result75% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3010 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 MOI | In-vitro result20% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3011 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.01 MOI | In-vitro result100% cell viability after 120 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3012 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result75% cell viability after 120 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3013 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result50% cell viability after 120 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3014 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration3 MOI | In-vitro result30% cell viability after 120 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3015 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 MOI | In-vitro result5% cell viability after 120 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3016 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationCPT (10nM) drug administered first and then virus | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.20 fraction of cell affected, shows antagonism (CI = 1.34) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3017 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus added first and then drug CPT drug administered (10nM) | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.19 fraction of cell affected, shows antagonism (CI = 1.66) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3018 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus and drug (10nM) co-administered | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.56 fraction of cell affected, shows synergism (CI = 0.11) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3019 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationCPT (30nM) drug administered first and then virus | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.25 fraction of cell affected, shows antagonism (CI = 1.75) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3020 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus added first and then drug CPT drug administered (30nM) | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.19 fraction of cell affected, shows antagonism (CI = 2.02) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3021 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus and drug (30nM) co-administered | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.65 fraction of cell affected, shows synergism (CI = 0.21) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3022 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationCPT (50nM) drug administered first and then virus | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.37 fraction of cell affected, shows antagonism (CI = 1.2) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3023 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus added first and then drug CPT drug administered (50nM) | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.13 fraction of cell affected, shows antagonism (CI = 5.12) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3024 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus and drug (50nM) co-administered | Immune gene insertion in viral genomeNo | Source of cell lineUniversity of toronto, canada | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayChou-talay method | In-vitro virus concentration0.1 MOI | In-vitro result0.69 fraction of cell affected, shows synergism (CI = 0.31) | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID31043633 |
| IDOV_3621 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result60% cell viability after day 3 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus in combination with induce apiptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID29485292 |
| IDOV_3622 | Virus nameMeasles virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result20% cell viability after day 6 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus in combination with induce apiptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID29485292 |
| IDOV_3635 | Virus nameMumps virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viability after day 3 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus in combination with induce apiptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID29485292 |
| IDOV_3636 | Virus nameMumps virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viability after day 6 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus in combination with induce apiptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID29485292 |
| IDOV_3649 | Virus nameMeasles and mumps virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationMeasles virus in combination with mumps virus | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result70% cell viability after day 3 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus in combination with induce apiptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID29485292 |
| IDOV_3650 | Virus nameMeasles and mumps virus | Virus strainwild type | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationMeasles virus in combination with mumps virus | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result18% cell viability after day 6 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus in combination with induce apiptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID29485292 |
| IDOV_3714 | Virus nameEnterovirus | Virus strainECHO-7 virus stain Rigvir | Virus genome typeRNA | Virus familyPicornaviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell linePublic health england | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell lineNA | In-vitro toxicityNA | AssayLive cell imaging system | In-vitro virus concentration1% virus concentration | In-vitro result27% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID29581783 |
| IDOV_3721 | Virus nameEnterovirus | Virus strainECHO-7 virus stain Rigvir | Virus genome typeRNA | Virus familyPicornaviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell linePublic health england | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell lineNA | In-vitro toxicityNA | AssayLive cell imaging system | In-vitro virus concentration10% virus concentration | In-vitro result24% cell viability | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID29581783 |
| IDOV_3859 | Virus nameNewcastle disease virus | Virus strainNDVstrain 320 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result67% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3860 | Virus nameNewcastle disease virus | Virus strainNDVstrain 27 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result67% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3861 | Virus nameNewcastle disease virus | Virus strainNDVstrain 852 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result67% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3862 | Virus nameNewcastle disease virus | Virus strainNDVstrain AD | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result70% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3863 | Virus nameNewcastle disease virus | Virus strainNDVstrain 860 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result72% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3864 | Virus nameNewcastle disease virus | Virus strainNDVstrain 753 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result74% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3865 | Virus nameNewcastle disease virus | Virus strainNDVstrain 429 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result75% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3866 | Virus nameNewcastle disease virus | Virus strainNDVstrain 718 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result82% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3867 | Virus nameNewcastle disease virus | Virus strainNDVstrain 770 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result84% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3868 | Virus nameNewcastle disease virus | Virus strainNDVstrain 264 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result84% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3869 | Virus nameNewcastle disease virus | Virus strainNDVstrain 777 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result84% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3870 | Virus nameNewcastle disease virus | Virus strainNDVstrain 776 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result86% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3871 | Virus nameNewcastle disease virus | Virus strainNDVstrain 922 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result86% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3872 | Virus nameNewcastle disease virus | Virus strainNDVstrain 14 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result90% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3873 | Virus nameNewcastle disease virus | Virus strainNDVstrain 49 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result90% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3874 | Virus nameNewcastle disease virus | Virus strainNDVstrain 321 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result92% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3875 | Virus nameNewcastle disease virus | Virus strainNDVstrain 945 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result94% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3876 | Virus nameNewcastle disease virus | Virus strainNDVstrain 52 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result94% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3877 | Virus nameNewcastle disease virus | Virus strainNDVstrain 48 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result94% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3878 | Virus nameNewcastle disease virus | Virus strainNDVstrain 329 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result99% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3879 | Virus nameNewcastle disease virus | Virus strainNDVstrain 746 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result99% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3880 | Virus nameNewcastle disease virus | Virus strainNDVstrain 53 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3881 | Virus nameNewcastle disease virus | Virus strainNDVstrain 389 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3882 | Virus nameNewcastle disease virus | Virus strainNDVstrain 12 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3883 | Virus nameNewcastle disease virus | Virus strainNDVstrain 373 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3884 | Virus nameNewcastle disease virus | Virus strainNDVstrain 465 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3885 | Virus nameNewcastle disease virus | Virus strainNDVstrain 769 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_3886 | Virus nameNewcastle disease virus | Virus strainNDVstrain 339 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell viability after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4001 | Virus nameNewcastle disease virus | Virus strainNDVwild 264 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result82% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4002 | Virus nameNewcastle disease virus | Virus strainNDVwild 264 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result82% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4003 | Virus nameNewcastle disease virus | Virus strainNDVwild 264 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result82% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4013 | Virus nameNewcastle disease virus | Virus strainNDVwild 320 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result100% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4014 | Virus nameNewcastle disease virus | Virus strainNDVwild 320 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result100% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4015 | Virus nameNewcastle disease virus | Virus strainNDVwild 320 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result70% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4025 | Virus nameNewcastle disease virus | Virus strainNDVwild 321 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result95% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4026 | Virus nameNewcastle disease virus | Virus strainNDVwild 321 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result70% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4027 | Virus nameNewcastle disease virus | Virus strainNDVwild 321 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result95% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4037 | Virus nameNewcastle disease virus | Virus strainNDVwild 373 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result100% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4038 | Virus nameNewcastle disease virus | Virus strainNDVwild 373 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result100% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4039 | Virus nameNewcastle disease virus | Virus strainNDVwild 373 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result100% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4049 | Virus nameNewcastle disease virus | Virus strainNDVwild 770 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result79% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4050 | Virus nameNewcastle disease virus | Virus strainNDVwild 770 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result80% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4051 | Virus nameNewcastle disease virus | Virus strainNDVwild 770 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result80% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4061 | Virus nameNewcastle disease virus | Virus strainNDVwild 852 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result62% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4062 | Virus nameNewcastle disease virus | Virus strainNDVwild 852 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result62% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4063 | Virus nameNewcastle disease virus | Virus strainNDVwild 852 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result62% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4073 | Virus nameNewcastle disease virus | Virus strainNDVwild 776 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration2 HAU | In-vitro result90% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4074 | Virus nameNewcastle disease virus | Virus strainNDVwild 776 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration8 HAU | In-vitro result90% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4075 | Virus nameNewcastle disease virus | Virus strainNDVwild 776 | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineRussian academy of science, Russia | Origin of cell lineHuman breast cancer adenocarcinoma cell line | Cell lineMCF-7 | Concentration of cell line10000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration16 HAU | In-vitro result80% cell survival after 4th day | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells | Immunogenic effectInduction of MARK signalling pathway | Clinical trialNA | PMID29621357 |
| IDOV_4081 | Virus nameAdenovirus | Virus strainAdenovirus ZD55 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationVirus encoded with drosophila dNK gene | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug BVDU(10mg/kg) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro resultSignificant reduction in cell growth | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induced apoptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID26203222 |
| IDOV_4082 | Virus nameAdenovirus | Virus strainAdenovirus ZD55 | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationVirus encoded with drosophila dNK gene | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with drug DFDC(10mg/kg) | Immune gene insertion in viral genomeNo | Source of cell lineShanghai cell collection | Origin of cell lineHuman breast cell line | Cell lineMCF-7 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro resultSignificant reduction in cell growth | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induced apoptosis in cancer cell | Immunogenic effectNA | Clinical trialNA | PMID26203222 |
| IDOV_4150 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4151 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result60% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4152 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result60% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4153 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result25% cell viability after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4154 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result10% cell viability after 7 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4155 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4156 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result40% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4157 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result30% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4158 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result10% cell viability after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4159 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result100% cell killing after 7 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4160 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4161 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result60% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4162 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result50% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4163 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result5% cell viability after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4164 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.1 MOI | In-vitro result100% cell killing after 7 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4165 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result100% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4166 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result20% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4167 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result15% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4168 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result2% cell viability after 6 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4169 | Virus nameMeasles virus | Virus strainMV-s-NAP | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line5000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration1 MOI | In-vitro result100% cell killing after 7 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis process leads to cancer cell death | Immunogenic effectVirus and drug both cause induction of IL-24 expression | Clinical trialIn clinical trials | PMID26272026 |
| IDOV_4324 | Virus nameAlphavirus | Virus strainM1 | Virus genome typeRNA | Virus familyTogaviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast adenocarcinoma | Cell lineMCF-7 | Concentration of cell line4000 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration10 pfu | In-vitro result95.2 % cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis | Immunogenic effectNA | Clinical trialNA | PMID26373347 |
| IDOV_4428 | Virus nameVesicular stomatitis virus | Virus strainRdB | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.2E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration21:1 particle to pfu | In-vitro result48% cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26430798 |
| IDOV_4436 | Virus nameVesicular stomatitis virus | Virus strainRdB-1L-VSVG | Virus genome typeRNA | Virus familyRhabdoviridae | Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line1.2E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration24:1 particle to pfu | In-vitro result1% cell survival after 4 days | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26430798 |
| IDOV_4477 | Virus nameAdenovirus | Virus strainoAD/DCN-shMet | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAdenovirus conjugated with DCN and shMet | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line70% confluence in 24 well plate | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration100 MOI | In-vitro result88% cancer cell survivalability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectIncreased in IL-6 level to 140pg/ml compared to control 20 pg/ml | Clinical trialNA | PMID26951927 |
| IDOV_4478 | Virus nameAdenovirus | Virus strainoAD/DCN-shMet/PP | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAdenovirus conjugated with DCN, shMet and PEGylated at PAMAM | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line70% confluence in 24 well plate | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration100 MOI | In-vitro result85% cancer cell survivalability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectIncreased in IL-6 level to 40pg/ml compared to control 20 pg/ml | Clinical trialNA | PMID26951927 |
| IDOV_4479 | Virus nameAdenovirus | Virus strainoAD/DCN-shMet/PPE | Virus genome typeDNA | Virus familyAdenoviridae | Virus genome modificationAdenovirus conjugated with DCN, shMet and Erbitux-conjugated PEGylated at PAMAM | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line70% confluence in 24 well plate | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration100 MOI | In-vitro result82% cancer cell survivalability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectIncreased in IL-6 level to 40pg/ml compared to control 20 pg/ml | Clinical trialNA | PMID26951927 |
| IDOV_5344 | Virus nameNewcastle disease virus | Virus strainLaSota | Virus genome typeRNA | Virus familyParamyxoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman mammary gland adenocarcinoma | Cell lineMCF-7 | Concentration of cell line5.0E+4 cells per well | In-vitro toxicityNA | AssayMTT assay | In-vitro virus concentration0.001 MOI | In-vitro result44% cells remain viable after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedVirus induce apoptosis | Immunogenic effectInduced production of IFN-alpha, IFN-beta, IL-6and IFN-gamma | Clinical trialNA | PMID28293547 |
| IDOV_5552 | Virus nameReovirus | Virus strainReovirus serotype 3 | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman breast cancer cell line | Cell lineMCF-7 | Concentration of cell line60% confluency | In-vitro toxicityNA | AssayNA | In-vitro virus concentration40 MOI | In-vitro resultCell viability drops from 93 to 16% after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis by virus infection | Immunogenic effectNA | Clinical trialNA | PMIDUS6994858 |